Identifying the mechanism underlying treatment failure for Salmonella Paratyphi A infection using next-generation sequencing - a case report

BMC Infectious Diseases
Hye-Ran ParkChoon-Mee Kim

Abstract

Salmonella is a notorious pathogen that causes gastroenteritis in humans and the emergence of resistance to third-generation cephalosporins and azithromycin have raised concern. There has been rare case of Salmonella Paratyphi A infection accompanied by spondylitis. Here, we report a case of initial antibiotic treatment failure in a Korean man with Salmonella Paratyphi A infection and conducted next-generation sequencing (NGS) to determine the cause of failure of initial treatment for Salmonella Paratyphi A infection. A 70-year-old man was admitted to Chosun University Hospital with reported consistent low back pain with a history of having 5 days of chills and fever in another hospital a month ago. He was administered ceftriaxone (2 g daily) for 18 days including initial treatment to cover Salmonella enterica. The antimicrobial susceptibility test using MIC plate, found that the identified organism was resistant to ciprofloxacin and nalidixic acid. Moreover, the Salmonella Paratyphi A isolates were found to have an MIC > 16 mg/L for azithromycin, as he had resistance to both azithromycin and nalidixic acid, the treatment was switched to a combination of ciprofloxacin and cefotaxime. We carried out next-generation sequencing (N...Continue Reading

References

Feb 7, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J WainC M Parry
May 1, 1999·The Pediatric Infectious Disease Journal·S K SahaS Saha
May 20, 1999·Lancet·E J ThrelfallS Lacey
Aug 30, 2005·Lancet·M K BhanShinjini Bhatnagar
Sep 27, 2005·The Lancet Infectious Diseases·Bradley A Connor, Eli Schwartz
Jul 15, 2006·The Journal of Antimicrobial Chemotherapy·Lilian PumbweHannah M Wexler
Feb 18, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shannon E MajowiczUNKNOWN International Collaboration on Enteric Disease 'Burden of Illness' Studies
Jun 4, 2010·The American Journal of Tropical Medicine and Hygiene·Trupti A PatelTom Doherty
Nov 14, 2012·Antimicrobial Agents and Chemotherapy·Marcus Ho Yin Wong, Sheng Chen
Jun 26, 2013·Antimicrobial Agents and Chemotherapy·Marcus Ho Yin WongSheng Chen
Jul 26, 2013·Japanese Journal of Infectious Diseases·Ja Young LeeJeong Nyeo Lee
Mar 25, 2014·Emerging Infectious Diseases·Robert-Jan HassingPerry J J van Genderen
Dec 3, 2014·Lancet·John WainR Leon Ochiai
Aug 7, 2017·Osong Public Health and Research Perspectives·Ki-Bok YoonJung-Beom Kim

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
ESR
PCR

Software Mentioned

HMMER
BLASTP
prodigal
CARD
minced
barrnap
RTA
bcl2fastq
Prokka
Aragon

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.